REDWOOD CITY, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Genomic Health, Inc. announced today that results from three new analyses of the company’s Oncotype DX(TM) breast cancer test, which quantifies the likelihood of recurrence and predicts chemotherapy benefit for a large portion of early stage breast cancer patients, will be presented at the 28th Annual San Antonio Breast Cancer Symposium, taking place December 8-11, 2005. Following are details for each embargoed session:
Friday, December 9 at 7:00 - 9:00 am (Central Time) Abstract #2049 Poster presentation: “Impact of Oncotype DX(TM) on decision making in breast cancer clinical practice.” Presenter: Ruth Oratz, M.D., NYU School of Medicine, New York, NY Saturday, December 10 at 10:45 am (Central Time) Abstract #29 Oral Presentation: “Association between the 21-gene recurrence score assay (RS) and risk of loco regional failure in node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.” Presenter: Eleftherios Mamounas, M.D., National Surgical Adjuvant Project (NSABP) -- a National Cancer Institute-funded cooperative study group, and Altman Health Foundation, Canton, OH Saturday, December 10 at 5:00 - 7:00 pm (Central Time) Abstract #310 Poster Presentation: “Measurement of gene expression using tissue microarray cores of paraffin embedded breast cancer tissue.” Presenter: Joffre Baker, M.D., Genomic Health, Inc., Redwood City, CA About Oncotype DX
Oncotype DX represents the first diagnostic multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. The test has been extensively evaluated in multiple independent studies involving more than 2,600 breast cancer patients, including a large validation study published in The New England Journal of Medicine. For more information about Oncotype DX, please visit www.oncotypedx.com.
About Genomic Health
Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(TM), which has been shown to predict the likelihood of breast cancer recurrence and chemotherapy benefit in early stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.
Genomic Health, Inc.
CONTACT: Emily Faucette, +1-415-946-1066, or Emily@weisscommpartners.com,or Katie Compa, +1-212-331-7813, or kcompa@weisscommpartners.com, both ofWeissComm Partners for Genomic Health, Inc.; or Brad Cole of GenomicHealth, Inc., +1-650-569-2281, or investors@genomichealth.com
Web site: http://www.genomichealth.com/
